Jonathan Yingling
Chief Tech/Sci/R&D Officer at ARCUS BIOSCIENCES, INC.
Profile
Jonathan Yingling is currently the Chief Scientific Officer at Arcus Biosciences, Inc. He previously held positions as Vice President-Oncology Discovery at Bristol Myers Squibb Co. from 2013 to 2015, and as Chief Scientific Officer & Senior Vice President at Idera Pharmaceuticals, Inc. from 2018 to 2020.
He also served as the Chief Scientific Officer at DNIB Unwind, Inc. Dr. Yingling completed his undergraduate degree at The College of William & Mary and obtained his doctorate from Duke University School of Medicine in 2016.
Jonathan Yingling active positions
| Companies | Position | Start |
|---|---|---|
| ARCUS BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 2019-12-31 |
Former positions of Jonathan Yingling
| Companies | Position | End |
|---|---|---|
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Chief Tech/Sci/R&D Officer | 2020-01-30 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 2015-09-30 |
| DNIB UNWIND INC | Chief Tech/Sci/R&D Officer | - |
Training of Jonathan Yingling
| The College of William & Mary | Undergraduate Degree |
| Duke University School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ARCUS BIOSCIENCES, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
DNIB Unwind, Inc.
 DNIB Unwind, Inc. BiotechnologyHealth Technology DNIB Unwind, Inc. develops biopharmaceutical preparations. The company was founded by Omid C. Farokhzad and Robert S. Langer on May 19, 2006 and is headquartered in Los Angeles, CA. | Health Technology |
- Stock Market
- Insiders
- Jonathan Yingling
